Formycon AG (LON:0W4N)

Market Cap	433.56M
Revenue (ttm)	51.55M
Net Income (ttm)	54.17M
Shares Out	n/a
EPS (ttm)	3.24
PE Ratio	8.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,624
Average Volume	3,024
Open	30.95
Previous Close	30.40
Day's Range	29.35 - 31.20
52-Week Range	29.90 - 80.20
Beta	0.81
RSI	18.10
Earnings Date	Mar 27, 2025

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company’s pipeline includes FYB202, a biosimilar candidate for Stelara used in ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1999
• Employees: 238
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0W4N

Financial Performance

In 2023, Formycon AG's revenue was 77.70 million, an increase of 82.83% compared to the previous year's 42.50 million. Earnings were 75.80 million, an increase of 110.59%.

Financial numbers in EUR